Proteomics-based identification of α-enolase as a tumor antigen in non-small lung cancer

Cancer Science

Volumn 98, Issue 8, 2007, Pages 1234-1240

  He, Ping ^a   Naka, Tetsuji ^a,b   Serada, Satoshi ^c   Fujimoto, Minoru ^a,b   Tanaka, Toshio ^a   Hashimoto, Shoji ^d   Shima, Yoshihito ^a   Yamadori, Tomoki ^a   Suzuki, Hidekazu ^e   Hirashima, Tomonori ^e   Matsui, Kaoru ^e   Shiono, Hiroyuki ^a   Okumura, Meinoshin ^a   Nishida, Toshiro ^a   Tachibana, Isao ^a   Norioka, Naoko ^c   Norioka, Shigemi ^c   Kawase, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY HOSPITAL   (Japan)

^e OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ENOLASE; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIBODY DETECTION; ARTICLE; CANCER CELL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG INFECTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MYCOBACTERIUM AVIUM; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; HUMANS; LUNG NEOPLASMS; PHOSPHOPYRUVATE HYDRATASE; PROTEIN ARRAY ANALYSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 34347253604     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00509.x     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E et.al. Cancer statistics. CA Cancer J Clin 2006; 56: 106-30.
2. Stieber P, Aronsson AC, Bialk P et.al. Tumor markers in lung cancer: EGTM recommendations. Anticancer Res 1999; 19: 2817-19.
3. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002; 2: 210-19.
4. Rastel D, Ramaioli A, Cornillie F, Thirion B. CYFRA 21-1, a sensitive and specific new tumor marker for squamous cell lung cancer. Eur J Cancer 1994; 30A: 601-6.
5. Trape J, Buxo J, Perez de Olaguer J, Vidal C. Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res 2003; 23: 4277-81.
6. Molina R, Agusti C, Mane JM et.al. CYFRA 21-1 in lung cancer: Comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 1994; 9: 96-101.
7. Lai RS, Hsu HK, Lu JY, Ger LP, Lai NS. CYFRA 21-1 enzyme-linked immunosorbent assay: Evaluation as a tumor marker in non-small cell lung cancer. Chest 1996; 109: 995-1000.
8. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002; 48: 1931-7.
9. Yamamoto A, Shimizu E, Ogura T, Sone S. Detection of auto-antibodies against 1-myc oncogene products in sera from lung cancer patients. Int J Cancer 1996; 69: 283-9.
10. Yamamoto A, Shimizu E, Takeuchi E et.al. Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology 1999; 56: 129-33.
11. Bergqvist M, Brattstrom D, Lamberg K et.al. The presence of anti-p53 antibodies in sera prior to thoracic surgery in non small cell lung cancer patients: Its implications on tumor volume, nodal involvement, and survival. Neoplasia 2003; 5: 283-7.
12. Blaes F, Klotz M, Huwer H et.al. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg 2000; 69: 254-8.
13. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001; 61: 7908-12.
14. Brichory FM, Misek DE, Yim AM et.al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001; 98: 9824-9.
15. Chang JW, Lee SH, Jeong JY et.al. Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett 2005; 579: 2873-7.
16. Humphrey LL, Teutsch S, Johnson M. US Preventive Services Task Force: lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: An update for the US Preventive Services Task Force. Ann Intern Med 2004; 140: 740-53.
17. Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol 2003; 21: 37-8.
18. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal Chem 1996; 68: 850-8.
19. Tsuruha J, Masuko-Hongo K, Kato T, Sakata M, Nakamura H, Nishioka K. Implication of cartilage intermediate layer protein in cartilage destruction in subsets of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2001; 44: 838-45.
20. Pancholi V. Multifunctional α-enolase: Its role in diseases. Cell Mol Life Sci 2001; 58: 902-20.
21. Imafuku Y, Omenn GS, Hanash S. Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis Markers 2004; 20: 149-53.
22. Chang YS, Wu W, Walsh G, Hong WK, Mao L. Enolase-α is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res 2003; 9: 3641-4.
23. Chen G, Gharib TG, Wang H et.al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA 2003; 100: 13.537-42.
24. Li LS, Kim H, Rhee H et.al. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of non-small cell lung carcinoma. Proteomics 2004; 4: 3394-400.
25. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004; 84: 1014-20.
26. Li C, Xiao Z, Chen Z et.al. Proteome analysis of human lung squamous carcinoma. Proteomics 2006; 6: 547-58.
27. Chang GC, Liu KJ, Hsieh CL et.al. Identification of α-enolase as an autoantigen in lung cancer: Its overexpression is associated with clinical outcomes. Clin Cancer Res 2006; 12: 5746-54.
28. Redlitz A, Fowler BJ, Plow EF, Miles LA. The role of an enolase-related molecule in plasminogen binding to cells. Eur J Biochem 1995; 227: 407-15.
29. Fujii A, Yoneda M, Ito T et.al. Autoantibodies against the amino terminal of α-enolase are a useful diagnostic marker of Hashimoto's encephalopathy. J Neuroimmunol 2005; 162: 130-6.